Skip to content
TrustList
Merck GHIF logo
Venture capital firm

Merck GHIF

Corporate venture fund from Merck investing in digital health and healthcare technology companies worldwide

  • Monitoring
  • Early Stage
  • North America
  • Security
  • +13 more
Merck GHIF cover

About Merck GHIF

Corporate venture capital for digital health

The Merck Global Health Innovation Fund, usually shortened to GHI, is the venture arm of the Merck pharmaceutical group. It says it is changing how corporate healthcare venture capital works by building a healthcare ecosystem strategy around its investments, and it reports more than sixty digital health deals. The fund invests across the world, with most of its attention on North America and Europe, and it puts money into platform companies whose technology or business model is already proven and where Merck's expertise can speed up revenue growth.

Where the fund looks

The fund describes its typical focus areas, with an emphasis on therapeutic areas where Merck is strong, oncology, the central nervous system, immunology and virology:

  • Therapy planning, meaning diagnostic and patient profiling tools that find undiagnosed patients, plus clinical decision support and care planning that give providers precise content for individual treatment recommendations.
  • Care management, covering care coordination that makes plans easier to follow, ways of educating and engaging patients, and population health monitoring that spots gaps in care and unnecessary costs.
  • Health analytics and artificial intelligence, which turn large data sets into real-world evidence and address interoperability, access and security of data.
  • Electronic clinical trials, with analytics and social platforms for choosing sites and recruiting subjects, and mobile and remote monitoring to keep participants engaged before, during and after a study.
  • Enabling technologies for biopharmaceutical operations, from clinical operations, regulation and pharmacovigilance to supply chain, sales and marketing, along with selective early-stage bets on technologies that could change the economics of the industry.

Stage and approach

Typical investments are companies that already have revenue, are close to profitability and want growth capital. The fund adds the weight of a strategic backer to a venture style of working: a streamlined process with the autonomy to make deals, a senior team with healthcare operating experience, and access to science, supply chain, commercial, marketing and regulatory specialists inside the parent group. It also points to Merck's operations and people in more than 140 countries and to a function that arranges collaborations between portfolio companies and the wider group.

TrustList summary

Merck GHIF, the Merck Global Health Innovation Fund, is the corporate venture arm of Merck. It backs digital health companies around the world, aiming to help them grow using the resources and healthcare expertise of its parent group.

Services

  • Digital health investment: capital for platform companies with proven technologies or business models, with more than 60 investments made.
  • Therapy planning: diagnostic and patient profiling tools, plus clinical decision support and care planning.
  • Care management: care coordination, patient education and engagement, and population health monitoring.
  • Health analytics and AI: turning large data sets into real-world evidence, with attention to data interoperability and security.
  • eClinical trials: better site selection, patient recruitment and protocol adherence through analytics and mobile tools.
  • Enabling technologies: tools for clinical operations, regulatory work, pharmacovigilance, supply chain, and sales and marketing.

Who it works with

The fund invests in healthcare technology companies, with a therapeutic emphasis on oncology, central nervous system disorders, immunology and virology. It also makes selective early-stage bets on emerging technologies.

Key facts

  • Parent: Merck
  • Investments: More than 60 in digital health
  • Therapeutic focus: Oncology, CNS, immunology and virology

Summary written by TrustList from the business's own published information, Nov 2026.

Categories & features

  • Monitoring
  • Early Stage
  • North America
  • Security
  • Science
  • Sales
  • Management
  • Education
  • Digital
  • Cloud
  • Face-to-Face
  • Commercial
  • Self-Learning
  • Analytics
  • Business
  • IoT
  • Marketing

Ask TrustList to introduce you to Merck GHIF

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA - Google Privacy Policy and Terms apply.

Reviews

Write the first review of Merck GHIF

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about Merck GHIF.

Merck GHIF alternatives

Similar listings buyers compare against this one.

Marketing technology group, formerly known as You & Mr Jones, that runs agencies and a venture arm

Pre-seed and seed investor in software and Web3 startups, active since 2019

Family of investment partnerships covering public equities, private placements and venture capital

Venture capital investor focused on seed and early-round technology companies, backed by cyber, construction and banking experience

Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Early-stage venture capital firm backing technology founders, based in Dallas